Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Altered cancer metabolism in mechanisms of immunotherapy resistance
Rishab Ramapriyan, Mauricio S. Caetano, Hampartsoum B. Barsoumian, et al.
Pharmacology & Therapeutics (2018) Vol. 195, pp. 162-171
Closed Access | Times Cited: 133

Showing 1-25 of 133 citing articles:

The cancer metabolic reprogramming and immune response
Longzheng Xia, Linda Oyang, Jinguan Lin, et al.
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 734
Metabolism of Amino Acids in Cancer
Zhen Wei, Xiaoyi Liu, Chunming Cheng, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 8
Open Access | Times Cited: 298
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Qian Sun, Zhenya Hong, Cong Zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 233
Immunotherapy in Renal Cell Carcinoma: The Future Is Now
Antoine Deleuze, Judikaël Saout, Frédéric Dugay, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 7, pp. 2532-2532
Open Access | Times Cited: 193
Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment
Peijie Wu, Wei Gao, Miao Su, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 158
Dysregulation of glutaminase and glutamine synthetase in cancer
José M. Matés, José A. Campos‐Sandoval, Juan de los Santos-Jiménez, et al.
Cancer Letters (2019) Vol. 467, pp. 29-39
Closed Access | Times Cited: 154
Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications
Xinyang Zhong, Xuefeng He, Yaxian Wang, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 152
Emerging strategies for treating metastasis
Mark Esposito, Shridar Ganesan, Yibin Kang
Nature Cancer (2021) Vol. 2, Iss. 3, pp. 258-270
Open Access | Times Cited: 117
Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity
Yuheng Yan, Lan Huang, Yiming Liu, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 108
Targeting the tumor biophysical microenvironment to reduce resistance to immunotherapy
Tian Zhang, Yuanbo Jia, Yang Yu, et al.
Advanced Drug Delivery Reviews (2022) Vol. 186, pp. 114319-114319
Closed Access | Times Cited: 76
Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma
Zhewen Xiong, Stephen L. Chan, Jingying Zhou, et al.
Gut (2023) Vol. 72, Iss. 9, pp. 1758-1773
Open Access | Times Cited: 54
Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment
Hari Menon, Rishab Ramapriyan, Taylor R. Cushman, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 133
Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity
Sara Verdura, Elisabet Cuyàs, Èric Cortada, et al.
Aging (2020) Vol. 12, Iss. 1, pp. 8-34
Open Access | Times Cited: 127
PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?
Nicola Fusco, Elham Sajjadi, Konstantinos Venetis, et al.
Genes (2020) Vol. 11, Iss. 7, pp. 719-719
Open Access | Times Cited: 114
Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance
Fang Wei, Dan Wang, Junyuan Wei, et al.
Cellular and Molecular Life Sciences (2020) Vol. 78, Iss. 1, pp. 173-193
Closed Access | Times Cited: 94
Enzymatically Formed Peptide Assemblies Sequestrate Proteins and Relocate Inhibitors to Selectively Kill Cancer Cells
Hongjian He, Shuang Liu, Difei Wu, et al.
Angewandte Chemie International Edition (2020) Vol. 59, Iss. 38, pp. 16445-16450
Open Access | Times Cited: 80
MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma
Ricardo Azevedo, Einav Shoshan, Shanzhi Whang, et al.
OncoImmunology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 72
CircRHBDD1 augments metabolic rewiring and restricts immunotherapy efficacy via m6A modification in hepatocellular carcinoma
Juan Cai, Zhiqiang Chen, Yao Zhang, et al.
Molecular Therapy — Oncolytics (2022) Vol. 24, pp. 755-771
Open Access | Times Cited: 66
Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application
Fusheng Zhang, Haiyang Liu, Meiqi Duan, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 59
The Effect of Oxidative Phosphorylation on Cancer Drug Resistance
Ziyi Zhao, Yong Mei, Ziyang Wang, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 62-62
Open Access | Times Cited: 54
From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement
Loïs Coënon, Martín Villalba
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 46
Overview of Cancer Metabolism and Signaling Transduction
Heesuk Chae, Seong‐Tshool Hong
International Journal of Molecular Sciences (2022) Vol. 24, Iss. 1, pp. 12-12
Open Access | Times Cited: 40
Alleviating hypoxia to improve cancer immunotherapy
Peng Fan, Naidong Zhang, Eleonora Candi, et al.
Oncogene (2023) Vol. 42, Iss. 49, pp. 3591-3604
Closed Access | Times Cited: 31
Immunotherapy resistance in solid tumors: mechanisms and potential solutions
Daniel S. Lefler, Steven Manobianco, Babar Bashir
Cancer Biology & Therapy (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 13
Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming
Ting Yu, Zhaoyun Liu, Qingxu Tao, et al.
Cancer Letters (2024) Vol. 589, pp. 216824-216824
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top